NCT05073250 2023-05-12IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.Chinese PLA General HospitalPhase 2 Unknown40 enrolled
NCT00989586 2017-02-06Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaOhio State University Comprehensive Cancer CenterPhase 1/2 Completed35 enrolled 11 charts